Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms AMG 305, AMG305 |
Target |
Action stimulants, modulators |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), CDH3 modulators(Cadherin 3 modulators), MSLN modulators(Mesothelin modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Lung Non-Small Cell Carcinoma | Phase 1 | United States | 29 Sep 2023 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 1 | Japan | 29 Sep 2023 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 1 | Australia | 29 Sep 2023 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 1 | Canada | 29 Sep 2023 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 1 | France | 29 Sep 2023 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 1 | Germany | 29 Sep 2023 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 1 | South Korea | 29 Sep 2023 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 1 | Spain | 29 Sep 2023 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 1 | United Kingdom | 29 Sep 2023 | |
| Breast Cancer | Phase 1 | United States | 29 Sep 2023 |






